Clinical Trials Browser

Phase 1 × Paclitaxel × 30 days × Clear all

NCT05673200 2026-03-18

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05954312 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

290 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasms

NCT07477743 2026-03-17

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

Phase 1 Recruiting

331 enrolled

Other solid neoplasm

Advanced Solid Tumor Cancer

NCT01374620 2026-03-16

PAL-ANGI2

Phase 1 Completed

28 enrolled

Tumor-Agnostic

Neoplasms

NCT03725436 2026-03-16

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Phase 1 Completed

28 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06173349 2026-03-13

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

12 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Active not recruiting

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05819892 2026-03-11

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

21 enrolled

Gynecologic

Endometrial Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Phase 1 Recruiting

20 enrolled

Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Phase 1 Active not recruiting

40 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06883630 2026-03-05

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Phase 1 Active not recruiting

121 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05307705 2026-03-02

PIKASSO-01

Phase 1 Active not recruiting

193 enrolled

Breast

Breast Neoplasms

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05381909 2026-02-20

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Phase 1 Terminated

157 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06333951 2026-02-19

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Recruiting

500 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms